The U.S. Food and Drug Administration (FDA) has recently approved expanded use of Amgen’s innovative product, marketed as Uplizna. This groundbreaking decision marks a significant milestone in the treatment of rare immune disorders. Also known as inebilizumab, Uplizna is the first FDA-approved therapy specifically targeting conditions associated with immunoglobulin G4 (IgG4-RD). This rare disorder, characterized by an overactive immune system that causes persistent inflammation and tissue scarring in vital organs such as the pancreas, liver, and kidneys, affects approximately 20,000 people across the United States.

The American pharmaceutical giant Amgen $AMGN is once again demonstrating its commitment to global growth by investing approximately 200 million dollars in a new technology hub in southern India. This move reinforces the company’s ambition to strengthen its presence in the so-called "pharmacy of the world" and leverage innovative technologies for drug development. During the event on Monday, CEO Robert Bradway emphasized that additional significant investments are planned in the coming years.

The American biotechnology company Amgen $AMGN has released its quarterly profit report, noting an impressive 11% increase in sales. In addition to this financial upturn, Amgen outlined ambitious plans for a key drug candidate aimed at combating obesity. However, the company faced regulatory setbacks as trials for another weight-loss drug were temporarily suspended, leading to some uncertainties in the market.